The DOI matches its Crossref record; 52 of the 54 references it cites were found in a registry or an index.
Somatic mutations affect key pathways in lung adenocarcinoma
Open accessAbstract
Determining the genetic basis of cancer requires comprehensive analyses of large collections of histopathologically well-classified primary tumours. Here we report the results of a collaborative study to discover somatic mutations in 188 human lung adenocarcinomas. DNA sequencing of 623 genes with known or potential relationships to cancer revealed more than 1,000 somatic mutations across the samples. Our analysis identified 26 genes that are mutated at significantly high frequencies and thus are probably involved in carcinogenesis. The frequently mutated genes include tyrosine kinases, among them the EGFR homologue ERBB4; multiple ephrin receptor genes, notably EPHA3; vascular endothelial growth factor receptor KDR; and NTRK genes. These data provide evidence of somatic mutations in primary lung adenocarcinoma for several tumour suppressor genes involved in other cancers--including NF1, APC, RB1 and ATM--and for sequence changes in PTPRD as well as the frequently deleted gene LRP1B. The observed mutational profiles correlate with clinical features, smoking status and DNA repair defects. These results are reinforced by data integration including single nucleotide polymorphism array and gene expression array. Our findings shed further light on several important signalling pathways involved in lung adenocarcinoma, and suggest new molecular targets for treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“While gain of 7p and loss of 8p have been previously reported to occur specifically in EGFR mutated adenocarcinomas16, 17, gain of 16p was a novel association.”
From Integrative Genomic Analyses Identifies GGA2 as a Cooperative Driver of EGFR-Mediated Lung Tumorigenesis (2019) · cites this paper as [17]
Experimental — accuracy not yet measuredIn the citing paper
“KRAS mutations predominate in NSCLCs, accounting for ~78% of all RAS mutations found in such tumours17. The activating missense KRAS mutations that occur in ~25% of NSCLCs19–23 are typically mutually exclusive with other clinically actionable driver mutations, such as those in EGFR, BRAF and ALK24.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [22]
In the citing paper
“Importantly, large-scale profiling studies utilizing either whole exome sequencing or broad targeted sequencing panels in NSCLC tumors have revealed multiple non-random patterns of co-occurring or mutually exclusive mutations, which typically vary depending on the particular oncogenic driver mutation15, 34, 58–62.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [60]
In the citing paper
“Activating mutations in KRAS are the most prevalent oncogenic driver event in both early-stage and metastatic LUAD, occurring in 25–32% of tumors34, 59, 60, 62, 67.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [60]
In the citing paper
“Similarly, mutations in ERBB4 were identified in cancer, particularly melanoma (Prickett et al., 2009), lung adenocarcinoma (Ding et al., 2008), and medulloblastoma (Gilbertson et al., 2001).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Ding et al., 2008
In the citing paper
“Gain/amplification of the mutant EGFR allele has previously been reported to frequently occur in LAC and is known to drive tumor progression17.”
From Integrative Genomic Analyses Identifies GGA2 as a Cooperative Driver of EGFR-Mediated Lung Tumorigenesis (2019) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Ferlay, J., Ward, E., & Forman, D. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 55,077
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,710
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Self-citationEGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationPao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citationEGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Self-citationPao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Self-citationThe Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161
Patterns of somatic mutation in human cancer genomes
Greenman, C. D., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G. R., Davies, H. R., Teague, J. W., Butler, A. P., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,143
Flagged first, then by citations
2 of the 54 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 601–700 of 1,007
Re, M. D., Tiseo, M., Bordi, P., D’Incecco, A., Camerini, A., Petrini, I., Lucchesi, M., Inno, A., Spada, D., Vasile, E., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6957 · Cited by 85
Merid, S. K., Goranskaya, D., & Alexeyenko, A. (2014) · BMC Bioinformatics · doi:10.1186/1471-2105-15-308 · Cited by 84
Targeted therapies in development for non-small cell lung cancer
Dy, G. K., & Reungwetwattana, T. (2013) · Journal of Carcinogenesis · doi:10.4103/1477-3163.123972 · Cited by 80
Leonetti, A., Assaraf, Y. G., Veltsista, P. D., Hassouni, B. E., Tiseo, M., & Giovannetti, E. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.11.002 · Cited by 81
Receptor-type protein tyrosine phosphatases in cancer
Du, Y., & Grandis, J. R. (2014) · 癌症：英文版 · doi:10.5732/cjc.014.10146 · Cited by 82
Loss of Connectivity in Cancer Co-Expression Networks
Anglani, R., Creanza, T. M., Liuzzi, V. C., Piepoli, A., Panza, A., Andriulli, A., & Ancona, N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087075 · Cited by 79
Elevated DDX21 regulates c-Jun activity and rRNA processing in human breast cancers
Zhang, Y., Baysac, K., Yee, L.-F., Saporita, A. J., & Weber, J. D. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0449-z · Cited by 80
A High-Dimensional, Deep-Sequencing Study of Lung Adenocarcinoma in Female Never-Smokers
Kim, S. C., Jung, Y., Park, J., Cho, S., Seo, C., Kim, J., Kim, P., Park, J., Seo, J., Kim, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055596 · Cited by 79
Recurrent inactivating mutations of ARID2 in non‐small cell lung carcinoma
Manceau, G., Letouzé, É., Guichard, C., Didelot, A., Cazes, A., Corté, H., Fabre, E., Pallier, K., Imbeaud, S., Pimpec‐Barthes, F. L., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27900 · Cited by 80
Breast cancer intratumour heterogeneity: current status and clinical implications
Joseph, C., Papadaki, A., Althobiti, M. M., Alsaleem, M. A., Aleskandarany, M. A., & Rakha, E. A. (2018) · Histopathology · doi:10.1111/his.13642 · Cited by 79
Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma
Flynt, E., Bisht, K. K., Sridharan, V., Ortiz, M., Towfic, F., & Thakurta, A. (2020) · Cells · doi:10.3390/cells9020287 · Cited by 79
Targeted therapies in the treatment of advanced/metastatic NSCLC
Pallis, A. G., Serfass, L., Dziadziuszko, R., van Meerbeeck, J. P., Fennell, D. A., Lacombe, D., Welch, J., & Gridelli, C. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.06.005 · Cited by 78
Cancer Stem Cell Division: When the Rules of Asymmetry Are Broken
Mukherjee, S., Kong, J., & Brat, D. J. (2014) · Stem Cells and Development · doi:10.1089/scd.2014.0442 · Cited by 77
Phase separation of EML4–ALK in firing downstream signaling and promoting lung tumorigenesis
Qin, Z., Sun, H., Yue, M., Pan, X., Chen, L., Feng, X., Yan, X., Zhu, X., & Ji, H. (2021) · Cell Discovery · doi:10.1038/s41421-021-00270-5 · Cited by 77
Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation
Groenendijk, F. H., Mellema, W. W., van der Burg, E., Schut, E., Hauptmann, M., Horlings, H. M., Willems, S. M., van den Heuvel, M. M., Jonkers, J., Smit, E. F., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29113 · Cited by 76
Activating ERBB4 mutations in non-small cell lung cancer
Kurppa, K. J., Denessiouk, K. A., Johnson, M. S., & Elenius, K. (2015) · Oncogene · doi:10.1038/onc.2015.185 · Cited by 76
Chen, C., Hsu, E., Lin, K., Tu, P., Chang, H.-W., Lin, C.-H., Chen, Y.-J., Gu, D.-L., Lin, C.-H., Wu, J.-Y., et al. (2010) · Hepatology · doi:10.1002/hep.23847 · Cited by 77
Mak, R. H., Hermann, G., Lewis, J. H., Aerts, H. J. W. L., Baldini, E. H., Chen, A. B., Colson, Y. L., Hacker, F., Kozono, D., Wee, J. O., et al. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.09.005 · Cited by 79
ATM and ATR signaling at a glance
Awasthi, P., Foiani, M., & Kumar, A. (2016) · Journal of Cell Science · doi:10.1242/jcs.188631 · Cited by 78
Eichner, L. J., Curtis, S. D., Brun, S. N., McGuire, C. K., Gushterova, I., Baumgart, J. T., Trefts, E., Ross, D. S., Rymoff, T. J., & Shaw, R. J. (2023) · Science Advances · doi:10.1126/sciadv.add3243 · Cited by 81
Molecular mechanisms of tumor suppression by LKB1
Vaahtomeri, K., & Mäkelä, T. P. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.12.034 · Cited by 78
Zhao, Y., Zhang, X., Guda, K., Lawrence, E., Qun, S., Watanabe, T., Iwakura, Y., Asano, M., Wei, L., Yang, Z., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914884107 · Cited by 76
LKB1 Regulated Pathways in Lung Cancer Invasion and Metastasis
Marcus, A. I., & Zhou, W. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181fbc28a · Cited by 76
Structural mutations in cancer: mechanistic and functional insights
Inaki, K., & Liu, E. T. (2012) · Trends in Genetics · doi:10.1016/j.tig.2012.07.002 · Cited by 75
Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers
Wen, W., Chen, W., Xiao, N., Bender, R. P., Ghazalpour, A., Tan, Z., Swensen, J. J., Millis, S. Z., Basu, G. D., Gatalica, Z., et al. (2015) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.04.003 · Cited by 76
Lozano, M. D., Echeveste, J. I., Abengozar‐Muela, M., Mejías, L. D., Idoate, M. A., Calvo, A., & de Andrea, C. E. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2017-0208-ra · Cited by 76
Genetic Alterations and Personalized Medicine in Melanoma: Progress and Future Prospects
Griewank, K., Scolyer, R. A., Thompson, J. F., Flaherty, K. T., Schadendorf, D., & Murali, R. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt435 · Cited by 77
Dishevelled has a YAP nuclear export function in a tumor suppressor context-dependent manner
Lee, Y., Kim, N. H., Cho, E. S., Yang, J. H., Cha, Y. H., Kang, H. E., Yun, J. S., Cho, S. B., Lee, S.-H., Paclíková, P., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04757-w · Cited by 74
Pulmonary adenocarcinoma: A renewed entity in 2011
Kadara, H. N., Kabbout, M., & Wistuba, I. I. (2011) · Respirology · doi:10.1111/j.1440-1843.2011.02095.x · Cited by 78
Self-citationLu, L., Luo, F., Liu, Y., Liu, X., Shi, L., Lü, X., & Liu, Q. (2015) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2015.09.016 · Cited by 75
Suzuki, M., Shiraishi, K., Yoshida, A., Shimada, Y., Suzuki, K., Asamura, H., Furuta, K., Kohno, T., & Tsuta, K. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.10.014 · Cited by 75
Fouret, R., Laffaire, J., Hofman, P. M., Beau‐Faller, M., Mazières, J., Validire, P., Girard, P., Camilleri‐Broët, S., Vaylet, F., Leroy-Ladurie, F., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0505 · Cited by 75
Discovery of cancer common and specific driver gene sets
Zhang, J., & Zhang, S. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx089 · Cited by 74
Dysregulated FGF signalling in neoplastic disorders
Tanner, Y., & Grose, R. P. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.10.012 · Cited by 78
DrGaP: A Powerful Tool for Identifying Driver Genes and Pathways in Cancer Sequencing Studies
Hua, X., Xu, H., Yang, Y., Zhu, J., Liu, P., & Lü, Y. (2013) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2013.07.003 · Cited by 76
Huang, M.-H., Lee, J., Chang, Y., Tsai, H.-H., Lin, Y., Lin, A. M.-Y., & Yang, J. C. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.09.002 · Cited by 74
Janes, P. W., Slape, C. I., Farnsworth, R. H., Atapattu, L., Scott, A. M., & Vail, M. E. (2014) · Growth Factors · doi:10.3109/08977194.2014.982276 · Cited by 75
Comparative Oncogenomics Implicates the Neurofibromin 1 Gene (NF1) as a Breast Cancer Driver
Wallace, M. D., Pfefferle, A. D., Shen, L., McNairn, A. J., Cerami, E. G., Fallon, B. L., Rinaldi, V. D., Southard, T. L., Perou, C. M., & Schimenti, J. C. (2012) · Genetics · doi:10.1534/genetics.112.142802 · Cited by 73
Lethal Mutagenesis: Targeting the Mutator Phenotype in Cancer
Fox, E., & Loeb, L. A. (2010) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.10.005 · Cited by 76
Somatic point mutations occurring early in development: a monozygotic twin study
Li, R., Montpetit, A., Rousseau, M., Wu, S., Greenwood, C. M. T., Spector, T. D., Pollak, M., Polychronakos, C., & Richards, J. B. (2013) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2013-101712 · Cited by 75
Smyd3-associated regulatory pathways in cancer
Giakountis, A., Moulos, P., Sarris, M. E., Hatzis, P., & Talianidis, I. (2016) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2016.08.008 · Cited by 76
Genomic Profiles Specific to Patient Ethnicity in Lung Adenocarcinoma
Broët, P., Dalmasso, C., Tan, E. H., Alifano, M., Zhang, S., Wu, J., Lee, M. H., Régnard, J., Lim, W., Koong, H. N., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2185 · Cited by 73
Gou, L.-Y., Niu, F., Wu, Y.-L. L. C., & Zhong, W. (2015) · Cancer · doi:10.1002/cncr.29531 · Cited by 71
Genomic impact of cigarette smoke, with application to three smoking-related diseases
Talikka, M., Sierro, N., Ivanov, N. V., Chaudhary, N. I., Peck, M. J., Hoeng, J., Coggins, C. R. E., & Peitsch, M. C. (2012) · Critical Reviews in Toxicology · doi:10.3109/10408444.2012.725244 · Cited by 74
Statistical method on nonrandom clustering with application to somatic mutations in cancer
Ye, J., Pavlı́ček, A., Lunney, E. A., Rejto, P. A., & Teng, C.-H. (2010) · BMC Bioinformatics · doi:10.1186/1471-2105-11-11 · Cited by 73
Emerging roles of Jab1/CSN5 in DNA damage response, DNA repair, and cancer
Pan, Y., Yang, H., & Claret, F. X. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.27823 · Cited by 73
The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein
Lucas, L. M., Dwivedi, V., Senfeld, J. I., Cullum, R. L., Mill, C. P., Piazza, J. T., Bryant, I. N., Cook, L. J., Miller, S. T., Lott, J. H., et al. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000381 · Cited by 70
TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade
Soussi, T. (2011) · Advances in cancer research · doi:10.1016/b978-0-12-386469-7.00005-0 · Cited by 77
ALK-rearrangements and testing methods in non-small cell lung cancer: a review
Shackelford, R. E., Vora, M., Mayhall, K., & Cotelingam, J. D. (2014) · Genes & Cancer · doi:10.18632/genesandcancer.3 · Cited by 72
Small Molecule Discoidin Domain Receptor Kinase Inhibitors and Potential Medical Applications
Li, Y., Lu, X., Ren, X., & Ding, K. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm5012319 · Cited by 72
Genomic Aberrations in Lung Adenocarcinoma in Never Smokers
Job, B., Bernheim, A., Beau‐Faller, M., Camilleri‐Broët, S., Girard, P., Hofman, P. M., Mazières, J., Toujani, S., Lacroix, L., Laffaire, J., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015145 · Cited by 72
Sirt3 is a tumor suppressor in lung adenocarcinoma cells
Xiao, K., Jiang, J., Wang, W., Cao, S., ZHU, L., Zeng, H., Ouyang, R., Zhou, R., & Chen, P. (2013) · Oncology Reports · doi:10.3892/or.2013.2604 · Cited by 72
Tessema, M., Yu, Y. Y., Stidley, C. A., Machida, E. O., Schuebel, K. E., Baylin, S. B., & Belinsky, S. A. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp114 · Cited by 72
Molecular Pathways: Targeting NRAS in Melanoma and Acute Myelogenous Leukemia
Johnson, D. B., Smalley, K. S. M., & Sosman, J. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3270 · Cited by 73
Imperial, R. J. L., Toor, O. M., Hussain, A., Subramanian, J., & Masood, A. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.016 · Cited by 74
Xu, C., Li, Y., Yue, P., Owonikoko, T. K., Ramalingam, S. S., Khuri, F. R., & Sun, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020899 · Cited by 71
Genomic profile analysis of diffuse-type gastric cancers
Lee, Y.-S., Cho, Y. S., Lee, G. K., Lee, S., Kim, Y., Jho, S., Kim, H., Hong, S.-H., Hwang, J.-A., Kim, S.-Y., et al. (2014) · Genome biology · doi:10.1186/gb-2014-15-4-r55 · Cited by 73
Aylon, Y., Yabuta, N., Besserglick, H., Buganim, Y., Rotter, V., Nojima, H., & Oren, M. (2009) · Oncogene · doi:10.1038/onc.2009.270 · Cited by 71
Targeting EGFR in non-small-cell lung cancer: Lessons, experiences, strategies
Stella, G. M., Luisetti, M., Inghilleri, S., Cemmi, F., Scabini, R., Zorzetto, M., & Pozzi, E. (2011) · Respiratory Medicine · doi:10.1016/j.rmed.2011.10.015 · Cited by 73
Wang, L., Stueckle, T. A., Mishra, A., Derk, R. C., Meighan, T. G., Castranova, V., & Rojanasakul, Y. (2013) · Nanotoxicology · doi:10.3109/17435390.2013.801089 · Cited by 71
A Review of HER4 (ErbB4) Kinase, Its Impact on Cancer, and Its Inhibitors
El–Gamal, M. I., Mewafi, N. H., Abdelmotteleb, N. E., Emara, M. A., Tarazi, H., Sbenati, R. M., Madkour, M. M., Zaraei, S., Shahin, A. I., & Anbar, H. S. (2021) · Molecules · doi:10.3390/molecules26237376 · Cited by 75
Cancer Genome Sequencing—An Interim Analysis
Fox, E., Salk, J. J., & Loeb, L. A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1231 · Cited by 70
Ipilimumab: its potential in non-small cell lung cancer
Tomasini, P., Khobta, N., Greillier, L., & Barlési, F. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011431718 · Cited by 69
Lineage factors and differentiation states in lung cancer progression
Cheung, W. K. C., & Nguyen, D. X. (2015) · Oncogene · doi:10.1038/onc.2015.85 · Cited by 71
Schaettler, M. O., Richters, M. M., Wang, A. Z., Skidmore, Z. L., Fisk, B. A., Miller, K. E., Vickery, T. L., Kim, A. H., Chicoine, M. R., Osbun, J. W., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0291 · Cited by 69
Self-citationNada, H., Lee, K., Gotina, L., Pae, A. N., & Elkamhawy, A. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105217 · Cited by 73
Bai, X., Guo, Z.-Q., Zhang, Y.-P., Fan, Z., Liu, L., Liu, L., Long, L.-L., Ma, S.-C., Wang, J., Fang, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36892-4 · Cited by 72
Glycyrrhizin Suppresses Lung Adenocarcinoma Cell Growth Through Inhibition of Thromboxane Synthase
Huang, R.-Y., Chu, Y.-L., Jiang, Z.-B., Chen, X., Zhang, X., & Zeng, X. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000356677 · Cited by 65
Farjah, F., Lou, F., Sima, C. S., Rusch, V. W., & Rizk, N. P. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182992421 · Cited by 69
Protein tyrosine phosphatases in glioma biology
Navis, A. C., van den Eijnden, M., Schepens, J. T. G., van Huijsduijnen, R. H., Wesseling, P., & Hendriks, W. J. A. J. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0614-0 · Cited by 71
The influence of race and ethnicity on the biology of cancer
Henderson, B. E., Lee, N. H., Seewaldt, V. L., & Shen, H. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3341 · Cited by 68
Self-citationDivergent viral presentation among human tumors and adjacent normal tissues
Cao, S., Wendl, M., Wyczalkowski, M., Wylie, K., Ye, K., Jayasinghe, R., Xie, M.-C., Wu, S., Niu, B.-F., Grubb, R., et al. (2016) · Scientific Reports · doi:10.1038/srep28294 · Cited by 67
Self-citationCdc6 contributes to cisplatin-resistance by activation of ATR-Chk1 pathway in bladder cancer cells
Chen, S., Chen, X., Xie, G., He, Y., Yan, D., Zheng, D., Li, S., Fu, X., Li, Y., Pang, X., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9616 · Cited by 70
Wei, B., Wu, F., Xing, W., Sun, H., Yan, C. W., Zhao, C., Wang, D., Chen, X., Chen, Y., Li, M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-96242-6 · Cited by 70
Czubak, K., Lewandowska, M. A., Klonowska, K., Roszkowski, K., Kowalewski, J., Figlerowicz, M., & Kozłowski, P. (2015) · Oncotarget · doi:10.18632/oncotarget.4351 · Cited by 69
Willers, H., Gheorghiu, L., Liu, Q., Efstathiou, J. A., Wirth, L. J., Krause, M., & von Neubeck, C. (2015) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2015.05.007 · Cited by 69
Lisabeth, E. M., Fernandez, C., & Pasquale, E. B. (2012) · Biochemistry · doi:10.1021/bi2014079 · Cited by 67
Personalized therapies in the cancer "omics" era
Ocaña, A., & Pandiella, A. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-202 · Cited by 68
Suzuki, A., Matsushima, K., Makinoshima, H., Sugano, S., Kohno, T., Tsuchihara, K., & Suzuki, Y. (2015) · Genome biology · doi:10.1186/s13059-015-0636-y · Cited by 68
Chemotherapy and targeted agents for thymic malignancies
Girard, N. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.29 · Cited by 68
PTP1B regulates Eph receptor function and trafficking
Nievergall, E., Janes, P. W., Stegmayer, C., Vail, M. E., Haj, F. G., Teng, S. W., Neel, B. G., Bastiaens, P. I. H., & Lackmann, M. (2010) · The Journal of Cell Biology · doi:10.1083/jcb.201005035 · Cited by 68
Brennan, K., Koenig, J. L., Gentles, A. J., Sunwoo, J. B., & Gevaert, O. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.02.025 · Cited by 67
Genetically informed lung cancer medicine
Pao, W. J., Iafrate, A. J., & Su, Z. (2010) · The Journal of Pathology · doi:10.1002/path.2788 · Cited by 69
Self-citationSchneider, M. R., & Yarden, Y. (2015) · Oncogene · doi:10.1038/onc.2015.372 · Cited by 69
Sequencing and phasing cancer mutations in lung cancers using a long-read portable sequencer
Suzuki, A., Suzuki, M., Mizushima‐Sugano, J., Frith, M. C., Makałowski, W., Kohno, T., Sugano, S., Tsuchihara, K., & Suzuki, Y. (2017) · DNA Research · doi:10.1093/dnares/dsx027 · Cited by 65
Simpson, L. M., Macartney, T., Nardin, A., Fulcher, L. J., Röth, S., Testa, A., Maniaci, C., Ciulli, A., Ganley, I. G., & Sapkota, G. P. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.06.013 · Cited by 71
Evolutionary dynamics at the tumor edge reveal metabolic imaging biomarkers
Jiménez-Sánchez, J., Bosque, J. J., Londoño, G. A. J., Molina-García, D., Martínez, Á., Pérez-Beteta, J., Ortega-Sabater, C., Martínez, A. F. H., Vicente, A. M. G., Calvo, G. F., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2018110118 · Cited by 67
Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer
Gower, A., Wang, Y., & Giaccone, G. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1165-y · Cited by 68
Zhang, Y., Kang, S., Fang, W., Hong, S., Liang, W., Yan, Y., Qin, T., Tang, Y., Jin, S., & Zhang, L. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.09.008 · Cited by 66
Self-citationSunaga, N., Kaira, K., Imai, H., Shimizu, K., 中野, 哲., Shames, D. S., Girard, L., Soh, J., Sato, M., Iwasaki, Y., et al. (2012) · Oncogene · doi:10.1038/onc.2012.402 · Cited by 67
Effects of Cancer-Associated EPHA3 Mutations on Lung Cancer
Zhuang, G., Song, W., Amato, K. R., Hwang, Y., Lee, K., Boothby, M. R., Ye, F., Guo, Y., Shyr, Y., Lin, L., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs297 · Cited by 68
Self-citationMolecular Pathways: Context-Dependent Approaches to Notch Targeting as Cancer Therapy
Egloff, A. M., & Grandis, J. R. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2258 · Cited by 67
Cho, K., Casteel, D. E., Prakash, P., Tan, L., van der Hoeven, D., Salim, A. A., Kim, C., Capon, R. J., Lacey, E., Cunha, S. R., et al. (2016) · Molecular and Cellular Biology · doi:10.1128/mcb.00365-16 · Cited by 67
Li, C., Lyu, J., & Meng, Q. H. (2017) · Journal of Cancer · doi:10.7150/jca.17958 · Cited by 67
Recent advances in gold and silver nanoparticle based therapies for lung and breast cancers
Malik, P., & Mukherjee, T. K. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.10.048 · Cited by 70
Ye, X., Yu, H. J., Jin, Y., Jing, X., Xu, M., Wan, Z., & Zhang, X. (2014) · The Clinical Respiratory Journal · doi:10.1111/crj.12100 · Cited by 66
FGFR4 Role in Epithelial-Mesenchymal Transition and Its Therapeutic Value in Colorectal Cancer
Peláez‐García, A., Barderas, R., Torres, S., Hernández-Varas, P., Teixidó, J., Bonilla, F., de Herreros, A. G., & Casal, J. I. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063695 · Cited by 66
Xu, W.-X., Qu, Q., Zhuang, H.-H., Teng, X.-Q., Wei, Y.-W., Luo, J., Dai, Y.-H., & Qu, J. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.92988 · Cited by 70
Cooper, W. A., O'Toole, S. A., Boyer, M. J., Horvath, L. G., & Mahar, A. M. (2011) · Pathology · doi:10.1097/pat.0b013e328342629d · Cited by 67
Wang, I., Snyder, J. E., Zhang, Y., Lander, J. M., Nakafuku, Y., Lin, J. A., Chen, G., Kalin, T. V., Whitsett, J. A., & Kalinichenko, V. V. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00355-12 · Cited by 67
Metadata
- Authors
- Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., Fulton, L., Fulton, R. S., Zhang, Q., Wendl, M. C., Lawrence, M. S., Larson, D. E., Chen, K., Dooling, D. J., Sabo, A., Hawes, A. C., Shen, H., Jhangiani, S. N., Lewis, L. R., Hall, O., Zhu, Y., Mathew, T., Ren, Y., Yao, J., Scherer, S. E., Clerc, K., Metcalf, G. A., Ng, B., Milosavljevic, A., Gonzalez-Garay, M. L., Osborne, J. R., Meyer, R., Shi, X., Tang, Y., Koboldt, D. C., Lin, L., Abbott, R., Miner, T. L., Pohl, C., Fewell, G., Haipek, C., Schmidt, H., Dunford-Shore, B. H., Kraja, A., Crosby, S. D., Sawyer, C. S., Vickery, T., Sander, S., Robinson, J., Winckler, W., Baldwin, J., Chirieac, L. R., Dutt, A., Fennell, T., Hanna, M., Johnson, B. E., Onofrio, R. C., Thomas, R. K., Tonon, G., Weir, B. A., Zhao, X., Ziaugra, L., Zody, M. C., Giordano, T., Orringer, M. B., Roth, J. A., Spitz, M. R., Wistuba, I. I., Ozenberger, B., Good, P. J., Chang, A. C., Beer, D. G., Watson, M. A., Ladanyi, M., Broderick, S., Yoshizawa, A., Travis, W. D., Pao, W., Province, M. A., Weinstock, G. M., Varmus, H. E., Gabriel, S. B., Lander, E. S., Gibbs, R. A., Meyerson, M., & Wilson, R. K.
- Affiliations
- Washington University in St. Louis (US)
- Broad Institute (US)
- Baylor College of Medicine (US)
- Brigham and Women's Hospital (US)
- Dana-Farber Cancer Institute (US)
- Max Planck Society (DE)
- University of Michigan (US)
- The University of Texas MD Anderson Cancer Center (US)
- National Institutes of Health (US)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Meyerson, Matthew
- Wilson, Richard K.
- ORCID
- Ding, Li
- Getz, Gad
- Wheeler, David A.
- Mardis, Elaine R.
- McLellan, Michael D.
- Cibulskis, Kristian
- Greulich, Heidi
- Muzny, Donna M.
- Morgan, Margaret B.
- Fulton, Lucinda
- Fulton, Robert S.
- Wendl, Michael C.
- Lawrence, Michael S.
- Larson, David E.
- Chen, Ken
- Sabo, Aniko
- Shen, Hua
- Jhangiani, Shalini N.
- Zhu, Yiming
- Ren, Yanru
- Yao, Jiqiang
- Scherer, Steven E.
- Metcalf, Ginger A.
- Ng, Brian
- Milosavljevic, Aleksandar
- Tang, Yuzhu
- Koboldt, Daniel C.
- Lin, Ling
- Pohl, Craig
- Crosby, Seth D.
- Vickery, Tammi
- Winckler, Wendy
- Chirieac, Lucian R.
- Dutt, Amit
- Fennell, Tim
- Johnson, Bruce E.
- Thomas, Roman K.
- Tonon, Giovanni
- Zody, Michael C.
- Giordano, Thomas
- Roth, Jack A.
- Wistuba, Ignacio I.
- Ozenberger, Bradley
- Chang, Andrew C.
- Beer, David G.
- Watson, Mark A.
- Ladanyi, Marc
- Broderick, Stephen
- Yoshizawa, Akihiko
- Travis, William D.
- Pao, William
- Province, Michael A.
- Weinstock, George M.
- Varmus, Harold E.
- Gabriel, Stacey B.
- Lander, Eric S.
- Gibbs, Richard A.
- Meyerson, Matthew
- Wilson, Richard K.
- Venue
- Nature
- Published
- 2008-10
- Volume
- 455
- Issue
- 7216
- Pages
- 1069-1075
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2694412
- OpenAlex
- W2163798887
- Cited by
- 2,681
- References
- 54
- Citations by year
- 2026: 21 · 2025: 48 · 2024: 53 · 2023: 122 · 2022: 124 · 2021: 149 · 2020: 147 · 2019: 145 · 2018: 121 · 2017: 141 · 2016: 158 · 2015: 206 · 2014: 254 · 2013: 213 · 2012: 227
- FWCI
- 167.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Deep Blue (University of Michigan) (submittedVersion)
- Max Planck Institute for Plasma Physics (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Funders
- Broad Institute
- National Human Genome Research Institute (U54HG003067)
- National Cancer Institute (U19CA084953, P50CA070907, R01CA154365)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- lung adenocarcinoma, somatic mutations, carcinogenesis, tyrosine kinase, EphA3, Eph receptors, KDR, NTRK, tumor suppressor, neurofibromatosis type 1, APC, RB1, ATM, PTPRD, LRP1B, smoking, DNA repair deficiency, signaling pathways, molecular targets, mutational landscape
- MeSH terms
- Adenocarcinoma, Bronchiolo-Alveolar, Female, Humans, Lung Neoplasms, Male, Mutation, Proto-Oncogenes, Gene Expression Regulation, Neoplastic, Genes, Tumor Suppressor, Gene Dosage
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
